The provision will enable whole genome sequencing for neonatal and paediatric patients in intensive care units within 48 ...

China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

Shares of gene-sequencing leader Illumina have fallen 15% from Friday. Rivals 10X Genomics and Pacific BioSciences of California lost 18% and 15%, respectively.

The "Genomic Data Analysis and Interpretation Market Opportunities and Strategies to 2033" report has been added to ...

Illumina (NASDAQ:ILMN – Get Free Report) was downgraded by investment analysts at Barclays from an “equal weight” rating to ...

A stand-alone sequencing approach was accurate, cost effective and efficient for analyzing resistant pathogens and ...

We recently published an article titled These 10 Companies Led Monday’s Downturn. In this article, we are going to take a ...

On Monday, for the second time in as many business days, Illumina (NASDAQ: ILMN) stock took it on the chin because of an ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

To come up with last week’s worst performers, we considered only the stocks with at least $2 billion in market capitalization ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...